A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension (APOTUS)

Allergan

Status and phase: Completed; Phase 4

Conditions: Ocular Hypertension; Glaucoma, Open-Angle

Treatments: Drug: 0.15% Brimonidine Tartrate

Study type: Interventional

Funder types: Industry

Identifiers

NCT02003534

CN-BRI-1002

Details and patient eligibility

About

This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.

Enrollment: 376 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of open-angle glaucoma or ocular hypertension

Exclusion criteria

• Used Alphagan® in previous 3 months

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

376 participants in 1 patient group

0.15% Brimonidine Tartrate

Experimental group

Description:

0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.

Treatment:

Drug: 0.15% Brimonidine Tartrate